+

WO1992003175A1 - Inhalation device - Google Patents

Inhalation device Download PDF

Info

Publication number
WO1992003175A1
WO1992003175A1 PCT/GB1991/001357 GB9101357W WO9203175A1 WO 1992003175 A1 WO1992003175 A1 WO 1992003175A1 GB 9101357 W GB9101357 W GB 9101357W WO 9203175 A1 WO9203175 A1 WO 9203175A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
drawer
inhalation
body portion
chamber
Prior art date
Application number
PCT/GB1991/001357
Other languages
French (fr)
Inventor
Stephen John Minshull
John Leck Hart
Steven Kent
Michael Trevor Shepherd
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017654A external-priority patent/GB9017654D0/en
Priority claimed from GB909024149A external-priority patent/GB9024149D0/en
Application filed by Fisons Plc filed Critical Fisons Plc
Publication of WO1992003175A1 publication Critical patent/WO1992003175A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0041Details of the piercing or cutting means with movable piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Definitions

  • This invention relates to an improved medicament inhalation device, more particularly to such a device for use with medicament capsules.
  • European Patent Application No 406893 discloses a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber.
  • the piercing means are slidably mounted on the drawer, and must be actuated in an additional action following introduction of a capsule to the emptying chamber. This may be difficult for those with impaired hand movement, for example the elderly.
  • capsules are dispensed into the drawer from a capsule magazine with their longitudinal axis in an upright position. It has been found that more than one capsule may be dispensed into the drawer at a time, creating the risk of overdosing if both capsules are pierced, or jamming of the drawer.
  • a further disadvantage of this device is a tendency for capsules dispensed into the drawer to fall into the emptying chamber horizontally, which also results in jamming of the drawer.
  • capsules sometimes move vertically once in the chamber, leading to ineffective piercing by the piercing means.
  • a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the drawer comprises a body portion upon which the piercing means are mounted, and a pushing portion which is slidably mounted on the body portion and which bears against the capsule during movement of the drawer from the loading position to the inhalation position, the arrangement being such that relative movement of the body portion and the pushing portion in the inhalation position of the drawer results in the drawer adopting a piercing configuration in which the capsule is pierced by the capsule piercing means.
  • the device of the invention has the advantage that transport and piercing of a capsule may be achieved in one action which firstly moves the drawer from the loading position to the inhalation position and then causes adoption of the piercing configuration by relative movement of t.ne body portion and the pushing portion.
  • the device will be more readily operated by those with impaired hand movement, and will be more convenient for others, than prior art devices which require more than one action to achieve transport and piercing of a capsule.
  • the pushing portion may be biassed away from the body portion of the drawer by biassing means, for example a compression spring.
  • the biassing means may act to automatically reverse the relative movement of the body portion and the pushing portion which results in adoption of the piercing configuration, so that inhalation may take place through the device.
  • the pushing portion is restrained by a stop when the drawer is in the inhalation position.
  • the stop (or stops) may be provided adjacent to the emptying chamber. In this case, appropriate movement of the body portion of the drawer results in adoption of the piercing configuration of the drawer.
  • the piercing means are covered by the pushing portion except when the drawer is in (or approaching) the piercing configuration.
  • This may be achieved by providing through-going apertures or channels in the pushing portion which receive the piercing means when the drawer is not in the piercing position, and which allow the piercing means to pass through during relative movement of the body portion and the pushing portion.
  • the piercing means may comprise two rods each having a sharpened end.
  • the ends of the rods may be sharpened to a point or a blade.
  • the rods may be formed in one piece, for example they may be parts of a U-shaped double ended pin.
  • the capsule emptying chamber has a capsule entrance whose width is less than the diameter of the capsule. This restricts the movement of a capsule between arrival in the drawer and introduction to the chamber. For example, such a feature may prevent capsules falling into a horizontal position when they are intended to be transported and pierced in a vertical position.
  • biassing means are also provided, their stiffness is preferably sufficiently great that the resistance offered by a capsule as it is urged through the capsule entrance by the pushing portion does not result in a substantial perturbation of the biassing means: for example where the biassing means is a compression spring, the spring is not substantially compressed.
  • devices of the invention comprise a capsule magazine from which capsules are dispensed into the body portion of the drawer, for example by falling under gravity.
  • Controlled, individual dispensing of capsules is facilitated by provision of a shutter member on the body portion of the drawer, which closes off the drawer from the magazine when the drawer is not in the loading position. This prevents further capsules entering the drawer, which could result in jamming of the drawer or an overdose being administered to a patient.
  • the shutter member prevents ingress of moisture to the capsules remaining in the magazine.
  • the shutter member is preferably arranged so that it may further act to restrain movement of the capsule in the emptying chamber during piercing of the capsule.
  • Conventional means for dispersing powder in an entrained airstream may be provided in the air outlet, for example grids through which the airstream passes.
  • a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the air outlet is provided with one or more air inlets.
  • the air outlet to be provided with a pair of diametrically opposed air inlets adjacent to the capsule emptying chamber, and two pairs of diametrically opposed air inlets at the end of the air outlet remote from the capsule emptying chamber.
  • devices according to this aspect of the invention are able to deliver medicament to a patient with a much greater proportion of the particles having a size in the respirable range.
  • respirable range we mean sizes sufficiently small to penetrate deep into the lungs during inhalation, ie those having a mass median diameter in the range l-10 ⁇ m.
  • such devices require less inhalatory effort by a patient to inhale through them.
  • Figure 1 is an exploded perspective view, partly cut away, of a medicament inhalation device according to the invention which comprises a base portion and a capsule magazine;
  • Figure 2 is a cross sectional view in the plane II-II-II of
  • Figure 1 of the base portion of the device with a drawer in a loading position
  • Figure 3 is a cross sectional view along the line III-III of Figure 2;
  • Figure 4 is a view similar to that of Figure 2, but with the drawer in an inhalation position;
  • Figure 5 is a cross sectional view along the line V-V of
  • Figure 6 is a view similar to that of Figure 2, but with the drawer in a capsule piercing configuration; and Figure 7 is a cross sectional view along the line VII-VII of Figure 6.
  • a medicament inhalation device comprises a generally cylindrical base portion 2, upon which is coaxially and rotatably mounted a cylindrical capsule magazine 4.
  • Base portion 2 defines an inner space 6 which is more readily seen in Figures 2-7.
  • a cuboid member 8 depends from the upper wall 10 of base portion 2 into space 6.
  • Member 8 defines an upright cylindrical capsule emptying chamber 12 towards its rear end which communicates with an opening 14 in the front of base portion 2 via an upright rectangular passageway 16 whose width is slightly less than the diameter of a capsule C.
  • Two tangential air inlets 18 are provided at the base of chamber 12 which communicate with space 6. Space 6 in turn communicates with the atmosphere via air inlets 20 which take the form of niches in the side wall of opening 14.
  • Passageway 16 is also provided with an upright cylindrical capsule receiving chamber 22 towards its front end.
  • Capsule emptying chamber 12 is provided with an air outlet 24 which extends into a cylindrical shaft 26 which projects vertically from upper wall 10 of base portion 2.
  • a cross piece 28 delimits chamber 12 from air outlet 24, and serves to prevent capsule C escaping from chamber 12 through air outlet 24, as well as producing air turbulence which disperses entrained medicament, during inhalation.
  • Two diametrically opposed air inlets 30 empty into air outlet 24 just above cross piece 28. Air inlets 30 communicate with space 6 via passageways 32 which commence as vertical channels on the rear surface of member 8 and run through wall 10 and the wall of shaft 26. The air admitted by air inlets 30 serves to disperse entrained medicament during inhalation, and also to reduce the inhalatory effort required to inhale through the device.
  • a grid (not shown) is provided across air outlet 24 towards the top of shaft 26, which also serves to disperse entrained medicament during inhalation.
  • Magazine 4 is mounted on shaft 26, and is provided with ten circumferentially arranged vertical bores 34 which are each adapted to receive three medicament capsules. Magazine 4 abuts a gasket 42 attached to wall 10 so as to make an air tight seal. The bottom opening of each bore 34 may be brought into communication successively with aligned openings 38 and 40 in gasket 36 and wall 10 respectively by rotation about shaft 26.
  • An annular gasket 42 seals the upper ends of bores 34, and an annular plate 44 provided with four downwardly facing channels 46 is retained on gasket 36 by mouthpiece 48 which makes a snap fitting connection with magazine 4.
  • Channels 46 define two pairs of diametrically opposed air inlets which empty into the upper portion of air outlet 24 and communicate with the atmosphere via openings 50 in the mouthpiece.
  • the air admitted by channels 46 acts similarly to that admitted by air inlets 30 mentioned above.
  • a drawer 52 is slidably mounted on member 8 and comprises a body portion 54 and a pushing portion 56 which is slidably mounted on body portion 54.
  • a horizontally disposed compression spring 70 connects body portion 54 to pushing portion 56.
  • Body portion 54 has a generally U-shaped cross section, with a shutter 58 extending horizontally from the top of its front end, and a U-shaped double ended pin 60 mounted therein.
  • Shutter 58 is received by a space between the front portion of member 8 and wall 10
  • the base of body portion 54 is received by a space between member 8 and the base of base portion 2.
  • Pushing portion 56 is generally cuboid, with a concave back surface 62, and a pair of lateral wings 64 on each side surface which are received by channels 66 on the inner surface of the side walls of body portion 54. Lateral wings 64 pass through lateral slots 65 formed in the side walls of member 8 when drawer 52 is in the inhalation position.
  • the two ends of pin 60 are slidably received by two bores 68 which run through pushing portion 56.
  • Each side wall of body portion 54 has a through going bore 72 through which space 6 communicates with air inlets 18 when the drawer is in the inhalation position.
  • the device is operated as follows. With drawer 52 in the loading position shown in Figures 2 and 3, capsule C may fall under gravity from its bore 34 in magazine 4 into capsule receiving chamber 22 through opening 38 in gasket 36 and opening 40 in wall 10. Drawer 52 is then pushed radially inward by applying pressure to the front end of body portion 54. As this movement takes place, shutter 58 passes under opening 40 and prevents a second capsule from entering drawer 52. Also, force is transmitted via spring 70 to pushing portion 56 which bears against capsule C with its concave rear surface 62. Capsule C is consequently urged through passageway 16, and because the width of the passageway is less than the diameter of capsule C, the capsule remains in an upright position which is desirable for optimum piercing and avoidance of jamming of the drawer. The stiffness of spring 70 is such that the force necessary to urge capsule C through passageway 16 does not compress it substantially.
  • capsule C is delivered to capsule emptying chamber 12, and surface 62 of pushing portion 56 makes up part of the vertical wall of chamber 12. Also, lateral wings 64 of pushing portion 56 abut the end of slots 65 in member 8. Further inward movement of body portion 54 results in relative movement of body portion 54 and pushing portion 56 since pushing portion 56 is unable to move further inward because of its abutment with the end of slot 65. Compression of spring 70 accompanies this relative movement.
  • the two ends of pin 60 move through bores 68 and penetrate into capsule emptying chamber 12, and shutter 58 passes over the top of chamber 12 which restricts the vertical movement of capsule C.
  • Pin 60 first moves capsule C into a vertical position and then penetrates the capsule in the piercing configuration of the drawer which is shown in Figures 6 and 7, producing two openings.
  • the pressure on bo:ly portion 54 is then released and spring 70 urges body portion 54 radially outward so that the device attains once again the inhalation position shown in Figures 4 and 5.
  • a patient then places his lips over mouthpiece 48 and inhales. Air is drawn through air inlets 20 into space 6 and from there into capsule emptying chamber 12 through bores 72 and air inlets 18. This movement of air causes the capsule to rotate about its longitudinal axis and undergo reciprocating movement along that axis, causing the powdered medicament to empty into chamber 12 through the openings made by the two ends of pin 60. The medicament is then entrained by the airstream and passes through air outlet 24 and into the patient. During inhalation, air is also drawn from space 6 into passageways 32 and through openings 50 to channels 46, from where it passes into air outlet 24 as described above.
  • body portion 54 is drawn radially outward to the loading position shown in Figures 2 and 3. During this movement, the emptied capsule leaves the device by falling through opening 74 in base portion 2, which is coaxial with capsule emptying chamber 12. On reaching the loading position, the next capsule falls into capsule receiving chamber 22, and the operation described above is repeated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A medicament inhalation device for use with medicament capsules comprises a capsule emptying chamber (12) provided with an air inlet (18) and an air outlet (24), and a drawer (52) for introduction of capsules (C) to the chamber, the drawer (52) being provided with capsule piercing means (60) and moveable between a loading position in which a capsule (C) may be placed therein and an inhalation position in which the capsule (C) is delivered to the emptying chamber (12), wherein the drawer (52) comprises a body portion (54) upon which the piercing means (60) are mounted, and a pushing portion (56) which is slidably mounted on the body portion and which bears against the capsule (C) during movement of the drawer (52) from the loading position to the inhalation position, the arrangement being such that relative movement of the body portion (54) and the pushing portion (56) in the inhalation position of the drawer results in the drawer (52) adopting a piercing configuration in which the capsule (C) is pierced by the capsule piercing means (60).

Description

INHALATION DEVICE This invention relates to an improved medicament inhalation device, more particularly to such a device for use with medicament capsules.
European Patent Application No 406893 (to Somova SpA, published after the priority date of the present invention) discloses a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber. In one embodiment of the device, the piercing means are slidably mounted on the drawer, and must be actuated in an additional action following introduction of a capsule to the emptying chamber. This may be difficult for those with impaired hand movement, for example the elderly.
In the device mentioned above, capsules are dispensed into the drawer from a capsule magazine with their longitudinal axis in an upright position. It has been found that more than one capsule may be dispensed into the drawer at a time, creating the risk of overdosing if both capsules are pierced, or jamming of the drawer. A further disadvantage of this device is a tendency for capsules dispensed into the drawer to fall into the emptying chamber horizontally, which also results in jamming of the drawer. In addition, capsules sometimes move vertically once in the chamber, leading to ineffective piercing by the piercing means.
We have now devised an improved mechanism for the transport and piercing of medicament capsules in a medicament inhalation device which is especially useful in inhalation devices of the type disclosed in European Patent Application No 406893.
According to the present invention, there is provided a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the drawer comprises a body portion upon which the piercing means are mounted, and a pushing portion which is slidably mounted on the body portion and which bears against the capsule during movement of the drawer from the loading position to the inhalation position, the arrangement being such that relative movement of the body portion and the pushing portion in the inhalation position of the drawer results in the drawer adopting a piercing configuration in which the capsule is pierced by the capsule piercing means.
The device of the invention has the advantage that transport and piercing of a capsule may be achieved in one action which firstly moves the drawer from the loading position to the inhalation position and then causes adoption of the piercing configuration by relative movement of t.ne body portion and the pushing portion. The device will be more readily operated by those with impaired hand movement, and will be more convenient for others, than prior art devices which require more than one action to achieve transport and piercing of a capsule.
We prefer the pushing portion to be biassed away from the body portion of the drawer by biassing means, for example a compression spring. The biassing means may act to automatically reverse the relative movement of the body portion and the pushing portion which results in adoption of the piercing configuration, so that inhalation may take place through the device.
Desirably, the pushing portion is restrained by a stop when the drawer is in the inhalation position. The stop (or stops) may be provided adjacent to the emptying chamber. In this case, appropriate movement of the body portion of the drawer results in adoption of the piercing configuration of the drawer.
Preferably, the piercing means are covered by the pushing portion except when the drawer is in (or approaching) the piercing configuration. This may be achieved by providing through-going apertures or channels in the pushing portion which receive the piercing means when the drawer is not in the piercing position, and which allow the piercing means to pass through during relative movement of the body portion and the pushing portion.
We prefer the piercing means to comprise two rods each having a sharpened end. The ends of the rods may be sharpened to a point or a blade. The rods may be formed in one piece, for example they may be parts of a U-shaped double ended pin.
Advantageously, the capsule emptying chamber has a capsule entrance whose width is less than the diameter of the capsule. This restricts the movement of a capsule between arrival in the drawer and introduction to the chamber. For example, such a feature may prevent capsules falling into a horizontal position when they are intended to be transported and pierced in a vertical position. Where biassing means are also provided, their stiffness is preferably sufficiently great that the resistance offered by a capsule as it is urged through the capsule entrance by the pushing portion does not result in a substantial perturbation of the biassing means: for example where the biassing means is a compression spring, the spring is not substantially compressed.
Preferably, devices of the invention comprise a capsule magazine from which capsules are dispensed into the body portion of the drawer, for example by falling under gravity.
Controlled, individual dispensing of capsules is facilitated by provision of a shutter member on the body portion of the drawer, which closes off the drawer from the magazine when the drawer is not in the loading position. This prevents further capsules entering the drawer, which could result in jamming of the drawer or an overdose being administered to a patient. Furthermore, where the device comprises a capsule magazine, the shutter member prevents ingress of moisture to the capsules remaining in the magazine. The shutter member is preferably arranged so that it may further act to restrain movement of the capsule in the emptying chamber during piercing of the capsule.
Conventional means for dispersing powder in an entrained airstream may be provided in the air outlet, for example grids through which the airstream passes.
According to a second aspect of the invention, there is provided a medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the air outlet is provided with one or more air inlets. We prefer the air outlet to be provided with a pair of diametrically opposed air inlets adjacent to the capsule emptying chamber, and two pairs of diametrically opposed air inlets at the end of the air outlet remote from the capsule emptying chamber.
It has been found that devices according to this aspect of the invention are able to deliver medicament to a patient with a much greater proportion of the particles having a size in the respirable range. By "respirable range" we mean sizes sufficiently small to penetrate deep into the lungs during inhalation, ie those having a mass median diameter in the range l-10μm. In addition, it has been found that such devices require less inhalatory effort by a patient to inhale through them.
We especially prefer devices which incorporate both aspects of the invention.
A preferred embodiment of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:
Figure 1 is an exploded perspective view, partly cut away, of a medicament inhalation device according to the invention which comprises a base portion and a capsule magazine;
Figure 2 is a cross sectional view in the plane II-II-II of
Figure 1 of the base portion of the device with a drawer in a loading position; Figure 3 is a cross sectional view along the line III-III of Figure 2;
Figure 4 is a view similar to that of Figure 2, but with the drawer in an inhalation position;
Figure 5 is a cross sectional view along the line V-V of
Figure 4;
Figure 6 is a view similar to that of Figure 2, but with the drawer in a capsule piercing configuration; and Figure 7 is a cross sectional view along the line VII-VII of Figure 6.
Referring first to Figure 1, a medicament inhalation device comprises a generally cylindrical base portion 2, upon which is coaxially and rotatably mounted a cylindrical capsule magazine 4.
Base portion 2 defines an inner space 6 which is more readily seen in Figures 2-7. A cuboid member 8 depends from the upper wall 10 of base portion 2 into space 6.
Member 8 defines an upright cylindrical capsule emptying chamber 12 towards its rear end which communicates with an opening 14 in the front of base portion 2 via an upright rectangular passageway 16 whose width is slightly less than the diameter of a capsule C. Two tangential air inlets 18 are provided at the base of chamber 12 which communicate with space 6. Space 6 in turn communicates with the atmosphere via air inlets 20 which take the form of niches in the side wall of opening 14. Passageway 16 is also provided with an upright cylindrical capsule receiving chamber 22 towards its front end.
Capsule emptying chamber 12 is provided with an air outlet 24 which extends into a cylindrical shaft 26 which projects vertically from upper wall 10 of base portion 2. A cross piece 28 delimits chamber 12 from air outlet 24, and serves to prevent capsule C escaping from chamber 12 through air outlet 24, as well as producing air turbulence which disperses entrained medicament, during inhalation. Two diametrically opposed air inlets 30 empty into air outlet 24 just above cross piece 28. Air inlets 30 communicate with space 6 via passageways 32 which commence as vertical channels on the rear surface of member 8 and run through wall 10 and the wall of shaft 26. The air admitted by air inlets 30 serves to disperse entrained medicament during inhalation, and also to reduce the inhalatory effort required to inhale through the device. A grid (not shown) is provided across air outlet 24 towards the top of shaft 26, which also serves to disperse entrained medicament during inhalation.
Magazine 4 is mounted on shaft 26, and is provided with ten circumferentially arranged vertical bores 34 which are each adapted to receive three medicament capsules. Magazine 4 abuts a gasket 42 attached to wall 10 so as to make an air tight seal. The bottom opening of each bore 34 may be brought into communication successively with aligned openings 38 and 40 in gasket 36 and wall 10 respectively by rotation about shaft 26. An annular gasket 42 seals the upper ends of bores 34, and an annular plate 44 provided with four downwardly facing channels 46 is retained on gasket 36 by mouthpiece 48 which makes a snap fitting connection with magazine 4. Channels 46 define two pairs of diametrically opposed air inlets which empty into the upper portion of air outlet 24 and communicate with the atmosphere via openings 50 in the mouthpiece. The air admitted by channels 46 acts similarly to that admitted by air inlets 30 mentioned above.
A drawer 52 is slidably mounted on member 8 and comprises a body portion 54 and a pushing portion 56 which is slidably mounted on body portion 54. A horizontally disposed compression spring 70 connects body portion 54 to pushing portion 56.
Body portion 54 has a generally U-shaped cross section, with a shutter 58 extending horizontally from the top of its front end, and a U-shaped double ended pin 60 mounted therein. Shutter 58 is received by a space between the front portion of member 8 and wall 10, and the base of body portion 54 is received by a space between member 8 and the base of base portion 2. Pushing portion 56 is generally cuboid, with a concave back surface 62, and a pair of lateral wings 64 on each side surface which are received by channels 66 on the inner surface of the side walls of body portion 54. Lateral wings 64 pass through lateral slots 65 formed in the side walls of member 8 when drawer 52 is in the inhalation position. The two ends of pin 60 are slidably received by two bores 68 which run through pushing portion 56. Each side wall of body portion 54 has a through going bore 72 through which space 6 communicates with air inlets 18 when the drawer is in the inhalation position.
The device is operated as follows. With drawer 52 in the loading position shown in Figures 2 and 3, capsule C may fall under gravity from its bore 34 in magazine 4 into capsule receiving chamber 22 through opening 38 in gasket 36 and opening 40 in wall 10. Drawer 52 is then pushed radially inward by applying pressure to the front end of body portion 54. As this movement takes place, shutter 58 passes under opening 40 and prevents a second capsule from entering drawer 52. Also, force is transmitted via spring 70 to pushing portion 56 which bears against capsule C with its concave rear surface 62. Capsule C is consequently urged through passageway 16, and because the width of the passageway is less than the diameter of capsule C, the capsule remains in an upright position which is desirable for optimum piercing and avoidance of jamming of the drawer. The stiffness of spring 70 is such that the force necessary to urge capsule C through passageway 16 does not compress it substantially.
In the inhalation position of the drawer shown in Figures 4 and 5, capsule C is delivered to capsule emptying chamber 12, and surface 62 of pushing portion 56 makes up part of the vertical wall of chamber 12. Also, lateral wings 64 of pushing portion 56 abut the end of slots 65 in member 8. Further inward movement of body portion 54 results in relative movement of body portion 54 and pushing portion 56 since pushing portion 56 is unable to move further inward because of its abutment with the end of slot 65. Compression of spring 70 accompanies this relative movement. The two ends of pin 60 move through bores 68 and penetrate into capsule emptying chamber 12, and shutter 58 passes over the top of chamber 12 which restricts the vertical movement of capsule C. Pin 60 first moves capsule C into a vertical position and then penetrates the capsule in the piercing configuration of the drawer which is shown in Figures 6 and 7, producing two openings. The pressure on bo:ly portion 54 is then released and spring 70 urges body portion 54 radially outward so that the device attains once again the inhalation position shown in Figures 4 and 5.
A patient then places his lips over mouthpiece 48 and inhales. Air is drawn through air inlets 20 into space 6 and from there into capsule emptying chamber 12 through bores 72 and air inlets 18. This movement of air causes the capsule to rotate about its longitudinal axis and undergo reciprocating movement along that axis, causing the powdered medicament to empty into chamber 12 through the openings made by the two ends of pin 60. The medicament is then entrained by the airstream and passes through air outlet 24 and into the patient. During inhalation, air is also drawn from space 6 into passageways 32 and through openings 50 to channels 46, from where it passes into air outlet 24 as described above.
To administer the contents of a subsequent capsule, body portion 54 is drawn radially outward to the loading position shown in Figures 2 and 3. During this movement, the emptied capsule leaves the device by falling through opening 74 in base portion 2, which is coaxial with capsule emptying chamber 12. On reaching the loading position, the next capsule falls into capsule receiving chamber 22, and the operation described above is repeated.

Claims

CLAIMS :
1. A medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the drawer comprises a body portion upon which the piercing means are mounted, and a pushing portion which is slidably mounted on the body portion and which bears against the capsule during movement of the drawer from the loading position to the inhalation position, the arrangement being such that relative movement of the body portion and the pushing portion in the inhalation position of the drawer results in the drawer adopting a piercing configuration in which the capsule is pierced by the capsule piercing means.
2. A device according to claim 1, wherein the pushing portion is biassed away from the body portion of the drawer by biassing means.
3. A device according to claim 1 or claim 2, wherein the pushing portion is restrained by a stop when the drawer is in the inhalation position.
4. A device according to any one of the preceding claims, wherein the piercing means are covered by the pushing portion when the drawer is not in the piercing configuration.
5. A device according to any one of the preceding claims, wherein the piercing means comprise two rods each having a sharpened end.
6. A device according to any one of the preceding claims, wherein the chamber has a capsule entrance whose width is less than the diameter of the capsule.
7. A device according to any one of the preceding claims. which further comprises a capsule magazine from which capsules are dispensed into the body portion of the drawer.
8. A device according to claim 7, wherein the body portion of the drawer is provided with a shutter member which closes off the drawer from the magazine when the drawer is not in the loading position.
9. A device according to any one of the preceding claims, wherein the air outlet is provided with one or more air inlets.
10. A medicament inhalation device for use with medicament capsules, comprising a capsule emptying chamber provided with an air inlet and an air outlet, and a drawer for introduction of capsules to the chamber, the drawer being provided with capsule piercing means and moveable between a loading position in which a capsule may be placed therein and an inhalation position in which the capsule is delivered to the emptying chamber, characterized in that the air outlet is provided with one or more air inlets.
PCT/GB1991/001357 1990-08-11 1991-08-09 Inhalation device WO1992003175A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9017654.6 1990-08-11
GB909017654A GB9017654D0 (en) 1990-08-11 1990-08-11 Improved device
GB9024149.8 1990-11-07
GB909024149A GB9024149D0 (en) 1990-11-07 1990-11-07 Inhalation device

Publications (1)

Publication Number Publication Date
WO1992003175A1 true WO1992003175A1 (en) 1992-03-05

Family

ID=26297496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/001357 WO1992003175A1 (en) 1990-08-11 1991-08-09 Inhalation device

Country Status (1)

Country Link
WO (1) WO1992003175A1 (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
WO1994014491A1 (en) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited Inhaler devices
EP0711572A4 (en) * 1994-05-26 1997-03-26 Unisia Jecs Corp Inhalation medicator and method of using the same
EP0869079A2 (en) 1997-04-04 1998-10-07 Plurichemie Anstalt Apparatus for orienting and positioning an elongate object for dispensing
US5896855A (en) * 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
EP0911047A1 (en) * 1993-06-03 1999-04-28 Boehringer Ingelheim Pharma KG Capsule holder
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
WO2001017595A1 (en) * 1999-09-04 2001-03-15 Innovata Biomed Limited Delivery device
WO2003000325A1 (en) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
US7025058B2 (en) 2001-04-26 2006-04-11 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
US7234464B2 (en) * 1999-12-18 2007-06-26 Meda Pharma Gmbh & Co. Kg. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
EP1844805A1 (en) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhaler
EP1891973A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1891974A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
WO2008107125A1 (en) 2007-03-02 2008-09-12 Almirall, S.A. New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives
US7464704B2 (en) 2001-11-23 2008-12-16 Innovata Biomed Limited Medicament delivery assembly
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010072354A1 (en) 2008-12-22 2010-07-01 Almirall, S.A. MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
WO2010097172A1 (en) 2009-02-27 2010-09-02 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
US7954492B2 (en) 2002-01-24 2011-06-07 Almirall, S.A. Pharmaceutical powder cartridge, and inhaler equipped with same
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
WO2012041476A1 (en) 2010-09-30 2012-04-05 Almirall, S.A. Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CN103052417A (en) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 Dry-powder inhaler
CN103052418A (en) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 Dry powder inhaler
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
EP2462973A3 (en) * 2004-09-15 2013-12-11 Optinose AS Nasal delivery devices
EP2707067A1 (en) * 2011-05-12 2014-03-19 Alfred Von Schuckmann Device for inhaling pulverulent substances
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
WO2014124757A1 (en) 2013-02-15 2014-08-21 Almirall, S.A. Pyrrolotriazine derivatives as pi3k inhibitors
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
WO2015091285A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
WO2016170009A1 (en) 2015-04-21 2016-10-27 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2019030298A1 (en) 2017-08-08 2019-02-14 Almirall, S.A. Novel compounds activating the nrf2 pathway

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1551053A (en) * 1966-09-17 1968-12-27
DE2704574A1 (en) * 1976-02-10 1977-08-11 Allen & Hanburys Ltd INHALATION DEVICE
EP0147755A2 (en) * 1983-12-17 1985-07-10 Boehringer Ingelheim Kg Inhalator
EP0406893A1 (en) * 1989-07-07 1991-01-09 SOMOVA S.p.A. Medicament inhalation device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1551053A (en) * 1966-09-17 1968-12-27
DE2704574A1 (en) * 1976-02-10 1977-08-11 Allen & Hanburys Ltd INHALATION DEVICE
EP0147755A2 (en) * 1983-12-17 1985-07-10 Boehringer Ingelheim Kg Inhalator
EP0406893A1 (en) * 1989-07-07 1991-01-09 SOMOVA S.p.A. Medicament inhalation device

Cited By (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
US5301666A (en) * 1991-12-14 1994-04-12 Asta Medica Aktiengesellschaft Powder inhaler
US5896855A (en) * 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
WO1994014491A1 (en) * 1992-12-24 1994-07-07 Rhone-Poulenc Rorer Limited Inhaler devices
EP0806214A3 (en) * 1992-12-24 1998-06-24 Rhone-Poulenc Rorer Limited Inhaler devices
EP0911047A1 (en) * 1993-06-03 1999-04-28 Boehringer Ingelheim Pharma KG Capsule holder
US5715811A (en) * 1994-05-26 1998-02-10 Unisia Jecs Corporation Inhaling type medicine administering device and using method therefor
EP0711572A4 (en) * 1994-05-26 1997-03-26 Unisia Jecs Corp Inhalation medicator and method of using the same
US5881721A (en) * 1997-04-04 1999-03-16 Plurichemie Anstalt Apparatus for orienting and positioning an elongate object for dispensing
EP0869079A2 (en) 1997-04-04 1998-10-07 Plurichemie Anstalt Apparatus for orienting and positioning an elongate object for dispensing
US7207330B1 (en) 1999-06-05 2007-04-24 Innovata Biomed Limited Delivery system
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10588895B2 (en) 1999-07-14 2020-03-17 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US10034867B2 (en) 1999-07-14 2018-07-31 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9687478B2 (en) 1999-07-14 2017-06-27 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
USRE46417E1 (en) 1999-07-14 2017-05-30 Almirall, S.A. Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US7571724B2 (en) 1999-09-04 2009-08-11 Innovata Biomed Limited Delivery device
AU779396B2 (en) * 1999-09-04 2005-01-20 Innovata Biomed Limited Delivery device
WO2001017595A1 (en) * 1999-09-04 2001-03-15 Innovata Biomed Limited Delivery device
US7571723B2 (en) 1999-09-04 2009-08-11 Innovata Biomed Limited Delivery device
US7219665B1 (en) 1999-09-04 2007-05-22 Innovata Biomed Limited Delivery device
US8820321B2 (en) 1999-12-18 2014-09-02 Almirall, S.A. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US8375940B2 (en) 1999-12-18 2013-02-19 Almirall, S.A. Storage system for powdered pharmaceuticals and inhaler equipped with this system
US7234464B2 (en) * 1999-12-18 2007-06-26 Meda Pharma Gmbh & Co. Kg. Storage system for powdered pharmaceuticals, and inhaler equipped with this system
US7025058B2 (en) 2001-04-26 2006-04-11 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
WO2003000325A1 (en) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder
US7464704B2 (en) 2001-11-23 2008-12-16 Innovata Biomed Limited Medicament delivery assembly
US7954492B2 (en) 2002-01-24 2011-06-07 Almirall, S.A. Pharmaceutical powder cartridge, and inhaler equipped with same
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
EP2774622A1 (en) 2004-05-31 2014-09-10 Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2292267A2 (en) 2004-05-31 2011-03-09 Almirall S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2002845A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
EP2002844A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarininc agents and beta-adrenergic agonists
EP2002843A2 (en) 2004-05-31 2008-12-17 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2138188A1 (en) 2004-05-31 2009-12-30 Almirall, S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP1905451A1 (en) 2004-05-31 2008-04-02 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
EP1891974A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP1891973A1 (en) 2004-05-31 2008-02-27 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
EP2774623A1 (en) 2004-05-31 2014-09-10 Almirall S.A. Combinations comprising antimuscarinic agents and beta-adrenergic agonists
EP2319538A2 (en) 2004-05-31 2011-05-11 Almirall S.A. Combinations combrising antimuscarinic agents and corticosteroids
US10398859B2 (en) 2004-09-15 2019-09-03 Optinose As Nasal delivery devices
EP2462973A3 (en) * 2004-09-15 2013-12-11 Optinose AS Nasal delivery devices
US7964615B2 (en) 2005-05-20 2011-06-21 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
US8242177B2 (en) 2005-05-20 2012-08-14 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor
EP2263998A1 (en) 2005-05-20 2010-12-22 Almirall S.A. Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
US8420669B2 (en) 2005-05-20 2013-04-16 Laboratories Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor
EP1844805A1 (en) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhaler
JP2015120074A (en) * 2006-04-13 2015-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhaler
WO2007118648A1 (en) * 2006-04-13 2007-10-25 Boehringer Ingelheim International Gmbh Inhaler
JP2009533111A (en) * 2006-04-13 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhaler
US8584669B2 (en) 2006-04-13 2013-11-19 Boehringer Ingelheim International Gmbh Inhaler
US8283342B2 (en) 2007-02-09 2012-10-09 Almirall S.A. Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
WO2008107125A1 (en) 2007-03-02 2008-09-12 Almirall, S.A. New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives
US8178679B2 (en) 2007-11-28 2012-05-15 Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2946769A1 (en) 2008-03-13 2015-11-25 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2946768A1 (en) 2008-03-13 2015-11-25 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954889A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954890A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2954891A1 (en) 2008-03-13 2015-12-16 Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma
US10085974B2 (en) 2008-03-13 2018-10-02 Almirall, S.A. Dosage and formulation
US11000517B2 (en) 2008-03-13 2021-05-11 Almirall, S.A. Dosage and formulation
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010072354A1 (en) 2008-12-22 2010-07-01 Almirall, S.A. MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR
US8563731B2 (en) 2008-12-22 2013-10-22 Almirall, S.A. Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
EP2221055A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
WO2010094484A1 (en) 2009-02-18 2010-08-26 Almirall, S.A. 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino}-l-hydroxyethyl) -8-hydroxyquin olin-2 (1h)-one and its use in the treatment of pulmonary diseases
EP2221297A1 (en) 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
WO2010094483A1 (en) 2009-02-18 2010-08-26 Almirall, S.A. 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
WO2010097172A1 (en) 2009-02-27 2010-09-02 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
US8524908B2 (en) 2009-03-12 2013-09-03 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2011057757A1 (en) 2009-11-11 2011-05-19 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2h)-one derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2011141180A1 (en) 2010-05-13 2011-11-17 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
CN103052418A (en) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 Dry powder inhaler
CN103052417A (en) * 2010-07-07 2013-04-17 阿普塔尔法国简易股份公司 Dry-powder inhaler
WO2012041476A1 (en) 2010-09-30 2012-04-05 Almirall, S.A. Pyridine and isoquinoline derivatives as syk- and jak-kinase inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012069175A1 (en) 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012069202A1 (en) 2010-11-26 2012-05-31 Almirall,S.A. Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US9737520B2 (en) 2011-04-15 2017-08-22 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
WO2012146667A1 (en) 2011-04-29 2012-11-01 Almirall, S.A. Imidazopyridine derivatives as pi3k inhibitors
EP2707067A1 (en) * 2011-05-12 2014-03-19 Alfred Von Schuckmann Device for inhaling pulverulent substances
WO2012160030A1 (en) 2011-05-25 2012-11-29 Almirall, S.A. Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
WO2013010881A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. NEW CRTh2 ANTAGONISTS
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
WO2013010880A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. New crth2 antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013017461A1 (en) 2011-08-01 2013-02-07 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9108918B2 (en) 2011-10-07 2015-08-18 Almirall, S.A. Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
WO2013068552A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
WO2013068554A1 (en) 2011-11-11 2013-05-16 Almirall, S.A. New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2013139712A1 (en) 2012-03-20 2013-09-26 Almirall, S.A. NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR.
US9346759B2 (en) 2012-03-20 2016-05-24 Almirall, S.A. Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
WO2013149959A1 (en) 2012-04-02 2013-10-10 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2013175013A1 (en) 2012-05-25 2013-11-28 Almirall, S.A. Novel dosage and formulation
EP2666465A1 (en) 2012-05-25 2013-11-27 Almirall, S.A. Novel dosage and formulation
WO2013178742A1 (en) 2012-05-31 2013-12-05 Almirall, S.A. Novel dosage form and formulation of abediterol
EP2668941A1 (en) 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
WO2014095920A1 (en) 2012-12-18 2014-06-26 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
WO2014124757A1 (en) 2013-02-15 2014-08-21 Almirall, S.A. Pyrrolotriazine derivatives as pi3k inhibitors
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015091285A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
WO2015091287A1 (en) 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
WO2016170009A1 (en) 2015-04-21 2016-10-27 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2019030298A1 (en) 2017-08-08 2019-02-14 Almirall, S.A. Novel compounds activating the nrf2 pathway

Similar Documents

Publication Publication Date Title
WO1992003175A1 (en) Inhalation device
US5320714A (en) Powder inhalator
EP0028162B1 (en) Breath actuated devices for administering powdered medicaments
US5337740A (en) Inhalation devices
EP0503031B1 (en) Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
EP0632734B1 (en) Powder jet dispenser for medicament inhalation therapies
US5388572A (en) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5429122A (en) Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
KR0177265B1 (en) Dry powder inhaler
US7461653B2 (en) Single dose inhaler
JP4195005B2 (en) Powder inhaler
CA2028192C (en) Multi-dose inhaler for medicaments in powder form
KR100321814B1 (en) Dry powder inhaler
HU216770B (en) Inhaler for administering powdered pharmaceutical preparations
EP0079478A1 (en) Medicament inhalation device
WO1992009322A1 (en) Inhalation device
CA2092614A1 (en) An inhaling device
DE69230179T2 (en) POWDER DISPENSER
EP0488609A1 (en) Powder inhaler
CN103096958A (en) Method for using a dry powder inhaler
JP4723785B2 (en) Powder inhaler
GB2061735A (en) Breath actuated device for administration of powdered medicaments by inhalation
WO2001015760A1 (en) Manually operated inhaler for substances in powder form
SI9210252A (en) Inhaler
AU2006225222A1 (en) Powder inhaler

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载